



# CECOG

Central European Cooperative Oncology Group

Ass.Prof.PD.Dr.Thorsten Füreder

General Assembly

3 June 2016

# History / Mission Statement

Oncologic centers in 23 countries are currently sharing their experience and originating new ideas through **CECOG**:

Austria

Bosnia

Bulgaria

Croatia

Cyprus

Czech Republic

Estonia

Greece

Hungary

Israel

Latvia

Lebanon

Lithuania

Montenegro

Poland

Portugal

Romania

Russia

Serbia

Slovenia

Slovakia

SouthAfrica

Turkey

# History / Mission Statement

Oncol  
their exp

Austria  
Bosnia  
Bulgaria  
Croatia  
Cyprus  
Czech Rep  
Estonia



ring  
ECOG:

a  
r  
rica

# History & Mission Statement

## *Mission Statement*

- CECOG has been formed to unite centers of clinical oncology from Central- and Southeastern Europe as well as Israel into a body devoted to conducting clinical trials and providing postgraduate education in oncology.
- We want to design and conduct controlled clinical trials in clinical oncology according to guidelines defined by Good Clinical Practice, perform these trials meticulously and analyze their results with the utmost scientific care.
- We strive to interact with the highest esteem for each other and with the overriding aim to improve the well-being and fate of patients.

# History & Mission Statement

## History


- 1999: Foundation of CECOG, non-profit oriented
- 2000: CECOG defined its mode of interaction based upon respect and mutual esteem in its Atlanta Declaration
- 2000: First two phase III clinical trials in metastatic breast cancer (MBC) and in non-small cell lung cancer (NSCLC) initiated
- 2002: Completion of first trials
- 2008: Educational activities started
- 1999-until present:

CECOG has implemented:




around 3000 patients

CECOG cooperates with more than:



in 23 countries

# Structure



# Structure

## CECOG Scientific Committee

consists of well known, academically established oncologists from the area of central and southeastern Europe each representing an academic institution of preeminent importance.

## CECOG Advisory board

consists of well-known, academically established oncologists of high international esteem from countries of the EU, Canada, Switzerland as well as from the region of Central and Southeastern Europe.

# Structure

## Office location and contact details

CECOG  
Schlagergasse 6/6  
A-1090 Vienna  
Austria



dagmar.just@cecog.at



+43/1/409 77 25

CECOG Office – 1090 Vienna [www.cecog.org](http://www.cecog.org)



# CECOG's capabilities in detail

## consulting & protocol development

Scientific advice and support

Design and clinical trial management

Evaluation of possible options for various indications

Clinical program review and „gap analysis“

Definition of intelligent trial endpoints

Statistical analysis plan and data programming

Definition of potential biomarkers

Close cooperation with cooperating partners

Involvement of international advisory board (optional)

# CECOG's capabilities in detail

## protocol implementation

Study site selection (incl. feasibility)

Investigator identification and recruitment

IRB and MOH submission, import licence, logistics for drug delivery

Fast patient enrolment and accrual strategies

High quality data generation via on-site-monitoring

Contracting, budget management and payment

Full regulatory compliance

No „competing trials“

Data collection, evaluation and statistical analysis

# Highlights of CECOG's trial management

Indication sites	Phase	No. patients	Recruiting	No. countries	No. period
Breast Cancer (recurrent or metastatic)	III	560	23 months	12	55
Breast Cancer (metastatic)	III	259	36 months	10	30
Breast Cancer (metastatic)	III	100	50 months	7	14
Breast Cancer (adjuvant)	II	50	12 months	2	3

# Highlights of CECOG's trial management

Indication sites	Phase	No. patients	Recruiting	No. countries	No. period
Lung, NSCLC	II	80	18 months	2	6
Lung, NSCLC	II	352	36 months	10	24
Colorectal	II	150	12 months	13	25
Colorectal	II	150	15 months	12	22
GIST	III	125	24 months	11	18
Prostate	III	376	36 months	16	51

# Intergroup Collaborations

*In the past:*

Pancreas

**CECOG/PAN 1.3.001 SAKK44/00** Phase III 3 sites, 57 patients

Cooperation with SAKK Switzerland

Colorectal, metastatic

**DREAM-MO18420** Phase III, 5 sites , 50 Patients

Cooperation with GERCOR France

*Current :*

**CECOG/BC.1.3.006 – GEICAM/PEARL Trial**, Phase III

Cooperation with the GEICAM Spain

Status: Recruiting



Thank you!